FIND First Quarter 2022 Financial Results April 29, 2022 w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n t h e u s H o l d i n g s , I n c . A l l r i g h t s r e s e r v e d 1 Mary Anne Heino President and CEO Bob Marshall CFO and Treasurer Paul Blanchfield Chief Commercial Officer Mark Kinarney Sr. Director, Investor Relations | --- | --- | --- | |-------|--------------------------------------|-------| | | 1Q 2022 Highlights & Business Update | | | | | | w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2318913 | | ...

1 ntheus Barclays Global Healthcare Conference Presentation March 15, 2022 FIND w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n t h e u s H o l d i n g s , I n c . A l l r i g h t s r e s e r v e d Safe Harbor Statements 2 Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provis ...

1 T M Investor Presentation February 2022 w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n t h e u s H o l d i n g s , I n c . A l l r i g h t s r e s e r v e d Safe Harbor Statements 2 Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities ...

heus FIND Fourth Quarter and Full Year 2021 Financial Results February 24, 2022 w w w . l a n t h e u s . c o m | © 2 0 2 2 L a n t h e u s H o l d i n g s , I n c . A l l r i g h t s r e s e r v e d 1 Mary Anne Heino President and CEO Bob Marshall CFO and Treasurer Paul Blanchfield Chief Commercial Officer Mark Kinarney Sr. Director, Investor Relations | --- | --- | |-------|--------------------------------------------------| | | | | | | | | 4Q & Full Year 2021 Highlights & Business Update | w w w . l a n ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) Q4 2021 Earnings Conference Call February 24, 2022 8:00 AM ET Company Participants Mary Anne Heino – President and Chief Executive Officer Mark Kinarney – Senior Director of Investor Relations Paul Blanchfield – Chief Commercial Officer Robert Marshall – Chief Financial Officer and Treasurer Conference Call Participants Danielle Antalffy – SVB Leerink Zach Wiener – Jefferies Lawrence Solow – CJS Securities Operator Good morning, ladies and gentlemen. And welcome to Lan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________ FORM 10-K _______________________________________________________________ (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File N ...

Financial Data and Key Metrics Changes - Revenue for Q3 2021 was $102.1 million, an increase of 15.3% compared to the prior year quarter [32] - Adjusted net income for the quarter was $5.7 million, an increase of 134.9% year-over-year [40] - Gross profit margin for the quarter was 50.1%, an increase of 270 basis points over the same period last year [35] Business Line Data and Key Metrics Changes - Precision diagnostics revenue was $87.9 million, up 9.8% year-over-year [33] - DEFINITY sales were $57.6 million, a 14.5% increase compared to the prior year quarter [33] - Radiopharmaceutical oncology revenue was $8.9 million, up 167.6% from the prior year, primarily due to PYLARIFY's launch [34] Market Data and Key Metrics Changes - PYLARIFY's launch saw significant momentum, with 20 PMFs activated by the end of Q3, covering approximately 70% of the U.S. population [13][17] - Hospitals accounted for approximately 65% of PYLARIFY orders, with independent imaging centers at 20% and government facilities at 15% [18] - The National Comprehensive Cancer Network included PSMA PET imaging in updated guidelines, enhancing PYLARIFY's market position [19] Company Strategy and Development Direction - The company aims to supplement DEFINITY supply with its own manufacturing facility, with an sNDA filed with the FDA [8] - Continued investment in PYLARIFY's commercial launch and expansion of the dedicated sales force is a priority [24] - The company is focused on achieving broad availability of PYLARIFY across the U.S. by year-end 2021 [22] Management's Comments on Operating Environment and Future Outlook - Management noted the impact of COVID-19 on elective procedures and hospital access, but expressed optimism about PYLARIFY's growth trajectory [6][45] - The company is monitoring staffing levels in hospitals, which could affect operations [6] - Management remains committed to sustainable growth across its portfolio while prioritizing patient outcomes [48] Other Important Information - The company expects Q4 2021 revenue to be in the range of $110 million to $115 million, reflecting a 17% to 22% increase year-over-year [42] - Adjusted EPS for Q4 is projected to be between $0.15 and $0.18, with full-year adjusted EPS raised to a range of $0.40 to $0.43 [43] Q&A Session Summary Question: Can you provide insights on PYLARIFY's performance and revenue? - Management confirmed that PYLARIFY's revenue was strong, with no inventory build due to the nature of radioisotope usage [51][53] - The company activated 20 PMFs by November 1, covering 70% of the U.S. population, and noted significant interest in PYLARIFY [55][65] Question: How is the company addressing staffing shortages in hospitals? - Management acknowledged broader staffing issues in healthcare and noted that these challenges have impacted AZEDRA more than PYLARIFY [68] Question: Can you elaborate on the guidance increase and PYLARIFY's role? - The guidance increase is primarily attributed to better-than-expected PYLARIFY performance, while other product lines may face headwinds [71][74] Question: What are the expectations for operating expenses and gross margins moving forward? - Management expects operating expenses to remain stable, with potential increases due to annualization of the sales team, while gross margins for PYLARIFY are anticipated to be above the company average [80]

Q3 2021 Financial Performance - The company reported worldwide revenues of $102.1 million, a 15.3% increase year-over-year[39, 41] - Adjusted EPS increased by 127.4% from $0.04 in Q3 2020 to $0.08 in Q3 2021[39] - Free cash flow decreased by 60.3% from $4.8 million in Q3 2020 to $1.9 million in Q3 2021[39] Product Performance - DEFINITY sales increased by 14.5%, with revenues of $57.6 million[41, 66] - TechneLite sales increased by 7.4%, with revenues of $22.7 million[41, 66] - Radiopharmaceutical oncology revenues increased by 167.5%, with revenues of $8.9 million[41, 66] PYLARIFY Launch and Expansion - PYLARIFY's manufacturing and distribution network expanded significantly, covering approximately 70% of the U S population by the end of Q3, up from approximately 6% at the start of the quarter[15] - The company contracted with approximately two-thirds (65%) of its targeted academic institutions in the U S for PYLARIFY[24, 25] Financial Guidance - The company updated its full-year 2021 revenue guidance to $405 million - $410 million[50, 51] - The company updated its full-year 2021 adjusted fully diluted EPS guidance to $0.40 - $0.43[50, 51]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2318913 ...